M ost pharmacists are familiar with the drug approval process, which consists of four phases of clinical trials. However, the FDA may now be revising the traditional process.
To review, drug studies generally begin on a small scale and advance cautiously as experience is gained in dosing and the duration of treatment is increased. After a potential new agent is tested in preclinical studies in in vitro and animal models, development moves to Phase I clinical trials.
A Phase I trial is the first use of a new agent in humans. The paramount goals of a Phase I trial are to establish a safe dosage range, determine safe routes of administration, and identify adverse reactions. Phase I trials are usually initiated in small patient populations at low doses. Healthy subjects are generally enrolled unless the drug possesses a significant toxicity profile. Some Phase I trials enroll subjects that have exhausted other treatment options.
If a drug demonstrates promising efficacy and safety characteristics during Phase I, development moves to Phase II. In general, the drug is now tested in smaller numbers of patients who have the condition that the drug is designed to treat. The purpose of these trials is to collect information on the effectiveness and safety in the anticipated patient population.
Trials then progress to Phase III, in which a larger number of subjects are treated with the agent than in Phase II, and typically for a longer period of time. Phase III studiesoften multicenter trials that focus the applicability of earlier findings to a broader group of patients -build on the experience gained in Phase II. After the Phase III trial, the applicant will submit a New Drug Application to the FDA, requesting approval of the agent for marketing. Following FDA review and approval, Phase IV monitoring studies may be initiated. Phase IV studies are postmarketing trials that help delineate benefits, optimal use, and potential side effects or drug interactions in larger groups of patients. Phase IV trials may be initiated by the FDA or by the sponsor; the advantage of this postmarketing surveillance is the accrual of additional data regarding the use of the drug in a diverse patient population -for example, those with multiple disease states or taking several medications.
At a recent Institute for International Research conference held in Washington DC, "Phase II Clinical Trials: Streamlining Proof of Efficacy," FDA Division of Clinical Trials Design and Analysis Team Leader Louis Marzella, MD, PhD, suggested that it may be time to abandon the Phase I to IV approach. He stated, "There's no straight set of requirements for each stage. The concept of sequential development is important but is certainly not necessary for all products and for all types of development . . . Lets consider a different classification…and look at study objectives . . . . This is a different way, a more sensible way of looking at clinical product development." 1 This type of development could be more consistent with the reality of how trial goals overlap from one phase to another.
Marzella went on to assert that as long as "critical agreements are reached (between FDA and sponsor) on how to develop a product," we can, "prevent the things that we all hate and like to avoid, such as multiple cycles of review." 1 Watch for a more objectivesbased approach to drug development that may differ between products. These objectives have not yet been established but could include safety and pharmacology, efficacy, and clinical utility. As health professionals, we need to be aware of potential changes in the drug approval process and how they may affect the dynamics of drugs once they are marketed. Improvements in the process are clearly welcome as long as the patient is ultimately served and protected.
